Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

October 21, 2008 09:00 ET

Urodynamix and Medical Measurement Systems Announce Worldwide Agreement to Expand Distribution for Bladder Product

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 21, 2008) - Urodynamix Technologies Ltd. ("Urodynamix") (TSX VENTURE:URO) today announced that it has entered into a worldwide distribution agreement with Medical Measurement Systems B.V. ("MMS"), a leading developer and distributor of medical diagnostic systems for urology, gastroenterology and neurology headquartered in the Netherlands.

In addition to traditional business terms for distribution, MMS will make additional royalty payments of 12% up to a maximum of $250,000 on product purchases. In exchange, MMS receives non-exclusive sales, marketing and distribution rights for acute care applications of Urodynamix's uroNIRS technology in North America and Europe, and non-exclusive sales, marketing and distribution rights worldwide for the uroNIRS 2000 Bladder Monitor System - a non-invasive medical device that uses NIRS to diagnose lower urinary tract symptoms (LUTS) in a urology office setting.

Along with their dominant presence in product innovation, development and distribution in the urodynamics markets throughout Europe and Asia, MMS has strong distribution channels in North America. Based on early sales performance in the research market, the agreement with MMS is a key part of Urodynamix's expansion strategy to partner with geographic market leaders and capitalize on significant opportunities globally for uroNIRS technology.

"Our non-invasive NIRS technology continues to present new opportunities for the diagnosis and treatment of lower urinary tract symptoms and prostate disease," said Barry Allen, CEO of Urodynamix. "MMS has the ability to effectively market our multiple uroNIRS technology platforms, and we expect to accelerate our sales penetration and minimize our costs by working with their existing specialized sales and distribution teams."

"MMS is a market leader in urodynamics and we are looking forward to introducing and promoting this exciting new technology," said Arjen J. de Weerd, President of MMS. "By integrating Urodynamix's uroNIRS technology with our Solar line of urodynamics systems we will continue to provide the latest advances in non-invasive diagnostic technology to our global customer base."

MMS expects to launch uroNIRS Bladder Monitor products in North America and Europe by the end of 2008 with sales commencing in 2009.

About Medical Measurement Systems B.V.

MMS has been producing urodynamic systems for more than 20 years, including Solar SmartFlow™ Urodynamics Systems and Flowmaster™ UroFlow products. MMS has an outstanding reputation for product development and innovation. Their engineers, sales and marketing teams have daily contact with practicing nurses and physicians all over the world, enabling MMS to develop diagnostic systems that exactly meet the needs of today's healthcare professionals.

The main corporate office of MMS is located in Enschede, the Netherlands, where all products are designed and tested to comply with American and European medical safety regulations as well as international quality standards.
Global distribution takes place through branch offices in the United States, Germany and The Netherlands and a worldwide network of highly qualified distributors who sell and service MMS systems to university, public and private hospitals in more than 60 countries.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information